Skip to content

Repligen RGEN Other Commercial Liabilities

Other Commercial Liabilities at other companies

TEC
Bio-TechneTECH
Revvity logo
RevvityRVTY
Danaher logo
DanaherDHR
Charles River Laboratories logo
Charles River LaboratoriesCRL
STERIS logo
STERISSTE
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's other commercial liabilities?
Repligen (RGEN) reported other commercial liabilities of $65.26M in Q1 2026.
How has Repligen's other commercial liabilities changed year-over-year?
Repligen's other commercial liabilities decreased by 14.2% year-over-year, from $76.04M to $65.26M.
What is the long-term trend for Repligen's other commercial liabilities?
Over 5 years (2020 to 2025), Repligen's other commercial liabilities has grown at a 8.3% compound annual growth rate (CAGR), from $53.09M to $79.21M.